Lexicon Pharmaceuticals Highlights Scientific and Medical Presentations Relating to Its Successful Phase 2 Proof-Of-Concept Study of LX9211 in Painful Diabetic Neuropathy

September 20, 2022

https://www.globenewswire.com/news-release/2022/09/20/2519255/0/en/Lexicon-Pharmaceuticals-Highlights-Scientific-and-Medical-Presentations-Relating-to-Its-Successful-Phase-2-Proof-Of-Concept-Study-of-LX9211-in-Painful-Diabetic-Neuropathy.html

Poster and Oral Presentation at PAINWeek Describing a Novel Mechanism of Action for Neuropathic Pain

Poster at International Association for the Study of Pain (IASP) World Congress on Pain Describing Design Elements of the RELIEF-DPN-1 Study

Read more at globenewswire.com

Related news for (LXRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.